Cite
LONG-TERM SAFETY OF TICAGRELOR MONOTHERAPY IN PATIENTS UNDERGOING PCI FOR STABLE CORONARY ARTERY DISEASE IN THE GLOBAL LEADERS STUDY: IMPACT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
MLA
Tomaniak, Mariusz, et al. “Long-Term Safety of Ticagrelor Monotherapy in Patients Undergoing Pci for Stable Coronary Artery Disease in the Global Leaders Study: Impact of Chronic Obstructive Pulmonary Disease.” Journal of the American College of Cardiology (JACC), vol. 73, no. 9, Mar. 2019, p. 196. EBSCOhost, https://doi.org/10.1016/S0735-1097(19)30804-6.
APA
Tomaniak, M., Chichareon, P., Takahashi, K., Kogame, N., Modolo, R., Chang, C. C., Katagiri, Y., Cano, E. S., Neumann, F.-J., Plante, S., Antolin, R. H., Gelev, V., Brunel, P., Beygui, F., Filipiak, K., van Geuns, R., Hamm, C., Storey, R., Soliman, O., & Onuma, Y. (2019). Long-Term Safety of Ticagrelor Monotherapy in Patients Undergoing Pci for Stable Coronary Artery Disease in the Global Leaders Study: Impact of Chronic Obstructive Pulmonary Disease. Journal of the American College of Cardiology (JACC), 73(9), 196. https://doi.org/10.1016/S0735-1097(19)30804-6
Chicago
Tomaniak, Mariusz, Ply Chichareon, Kuniaki Takahashi, Norihiro Kogame, Rodrigo Modolo, Chun Chin Chang, Yuki Katagiri, et al. 2019. “Long-Term Safety of Ticagrelor Monotherapy in Patients Undergoing Pci for Stable Coronary Artery Disease in the Global Leaders Study: Impact of Chronic Obstructive Pulmonary Disease.” Journal of the American College of Cardiology (JACC) 73 (9): 196. doi:10.1016/S0735-1097(19)30804-6.